Clinical Trials Logo
  1. Home
  2. Anemia of Chronic Kidney Disease
  3. NCT06463236
  4. Details
NCT06463236 Clinical Trial

Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients

Anemia of Chronic Kidney Disease Clinical Trial

Official title:
Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06463236
Other study ID # 01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 14, 2024
Est. completion date August 31, 2025

Study information
Verified date June 2024
Source Sichuan Provincial People's Hospital
Contact Daqing Hong
Phone 17716168101
Email hongdaqing11@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This test aims to verify that the management process of renal anemia in maintenance hemodialysis patients can improve the hemoglobin compliance rate better than that of anemia management by primary doctors, and promote the system at the grassroots level to guide primary doctors in anemia management and improve the management standard of renal anemia in maintenance hemodialysis patients through prospective randomized controlled trials. To improve the anemia compliance rate of maintenance hemodialysis patients, and to improve the basic doctors' grasp of the anemia management guidelines, consensus and standard operating procedures.

Recruitment information / eligibility
Status Recruiting
Enrollment 1296
Est. completion date August 31, 2025
Est. primary completion date July 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: ? Age over 18 years old; ? Receive regular hemodialysis at least twice a week for at least 3 months, and have no plans to stop hemodialysis within 6 months since the start of the trial; ? The patient voluntarily participated in this study. Exclusion Criteria: - Patients who have planned to undergo kidney transplantation or terminate hemodialysis during the study period; ? Previous history of bone marrow hematopoietic system diseases, such as combined myelodysplastic syndrome, multiple myeloma, and other diseases; ? Any known hereditary blood disease, such as thalassemia, sickle cell anemia, pure red blood cell aplasia, etc.; ? Active or chronic gastrointestinal bleeding; ? There was a severe infection within one week prior to screening.

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Guiding treatment
Standardized guidance for anemia treatment by grassroots doctors using the maintenance hemodialysis renal anemia management process
• empirical therapy
Experiential treatment by grassroots doctors

Locations
Country Name City State
China Sichuan Provincial People's Hospital Chengdu Sichuan

Sponsors (1)
Lead Sponsor Collaborator
Hong Daqing

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Changes in the one-year compliance rate of renal anemia Changes in renal anemia compliance rates between the experimental group and the control group within one year one year
See also
  Status Clinical Trial Phase
Completed NCT03325621 - Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients Phase 1/Phase 2
Completed NCT02198495 - Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients Phase 4
Suspended NCT03193073 - Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient N/A
Completed NCT02581124 - Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease Phase 1
Completed NCT02268994 - KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD Phase 3
Completed NCT04543812 - PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD Phase 3
Recruiting NCT05900635 - Effect of Adding Lactoferrin on Oral Iron on Anemia in Chronic Kidney Disease Patients Phase 4
Completed NCT04667533 - Desidustat in the Treatment of Chemotherapy Induced Anemia Phase 1
Completed NCT03731741 - Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients? Phase 2
Completed NCT02787824 - Periodic Versus Continuous IV Iron Supplementation in HD Patients Phase 4
Completed NCT03431623 - CKD-11101 Phase 3 SC Study Phase 3
Completed NCT01971164 - Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease Phase 1
Recruiting NCT01532349 - Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease Phase 2
Completed NCT05698420 - Investigation of the Effects of Medium Cut-off Dialyzers Versus High-Flux Dialyzers on Clinical and Laboratory Parameters of Prevalent Hemodialysis Patients
Completed NCT03427801 - Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease
Recruiting NCT03521713 - To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex) Phase 3
Active, not recruiting NCT02754167 - Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients Phase 1/Phase 2
Completed NCT02805244 - Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis Phase 1
Completed NCT03428594 - CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis Phase 3
Not yet recruiting NCT06352138 - Comparative Study of Two Recombinant Human Erythropoietin Products on Chronic Kidney Disease Patients Phase 3